IDMIT is a national infrastructure funded in 2012 by the national “programme d’investissements d’avenirs” (PIA). The Life Sciences Division of the CEA, the “Institut Pasteur”, the “Institut National de la Santé et de la Recherche Médicale” (Inserm), the “Agence Nationale de Recherche sur le SIDA et les Hépatites Virales” (ANRS), the Paris Sud 11 University (UPS-11), and BertinPharma, a CRO specialized on bioassays development and preclinical and clinical studies, have joined their forces to create a preclinical and technological research infrastructure focused on human infectious diseases, vaccines and innovative therapies. There is no equivalent infrastructure in Europe which combines the complementary expertise of the partners, all international leaders in the field, with the outstanding core facilities implemented in IDMIT for monitoring diseases and treatments including advanced technologies for high dimensional cell phenotyping (CyTof) and in vivo imaging (Near Infra Red fluorescence, two-photon microscope, confocal-endo microscopy, PET-CT).
The major objective of IDMIT is to provide the national and international scientific community with a highly competitive infrastructure for preclinical research, facilitating the discovery of markers of safety and efficacy of new vaccines and treatments and accelerating the translation of innovations from the bench to clinical practice.